Last update 01 Nov 2024
TQB-3909
Last update 01 Nov 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism Bcl-2 inhibitors(Apoptosis regulator Bcl-2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
15
Clinical Trials associated with TQB-3909A Phase Ib/II Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Moderate- and High-risk Myelofibrosis
评估TQB3909片联合阿扎胞苷在髓系恶性肿瘤受试者中安全性、有效性和药代动力学的Ib/II期临床试验
[Translation] A Phase Ib/II clinical trial evaluating the safety, efficacy, and pharmacokinetics of TQB3909 tablets combined with azacitidine in subjects with myeloid malignancies
TQ05105片联合TQB3909片治疗中高危骨髓纤维化的Ib/II期临床研究
[Translation] Phase Ib/II clinical study of TQ05105 tablets combined with TQB3909 tablets in the treatment of intermediate- and high-risk myelofibrosis
100 Clinical Results associated with TQB-3909
Login to view more data
100 Translational Medicine associated with TQB-3909
Login to view more data
100 Patents (Medical) associated with TQB-3909
Login to view more data
100 Deals associated with TQB-3909
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Primary Myelofibrosis | Phase 2 | CN | 13 May 2024 | |
| Acute Myeloid Leukemia | Phase 2 | CN | 25 Apr 2024 | |
| Myelodysplastic Syndromes | Phase 2 | CN | 25 Apr 2024 | |
| Myeloid Tumor | Phase 2 | CN | 25 Apr 2024 | |
| Chronic Lymphocytic Leukemia | Phase 2 | CN | 11 Oct 2023 | |
| Small Lymphocytic Lymphoma | Phase 2 | CN | 11 Oct 2023 | |
| Mantle cell lymphoma recurrent | Phase 2 | CN | 20 Sep 2023 | |
| Mantle cell lymphoma refractory | Phase 2 | CN | 20 Sep 2023 | |
| Advanced breast cancer | Phase 2 | CN | 02 Mar 2023 | |
| HR Positive/HER2 Negative/Node positive breast cancer | Phase 2 | CN | 02 Mar 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | 69 | (CLL/SLL) | (uwrzdwsiim) = None fbzzgdfssu (twvyacxcgd ) View more | Positive | 13 Sep 2024 | ||
(B-NHL) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free